Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Preferred Shares (2016 - 2025)

CorMedix (CRMD) has disclosed Preferred Shares for 12 consecutive years, with $92.0 as the latest value for Q3 2025.

  • Quarterly Preferred Shares fell 49.45% to $92.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $92.0 through Sep 2025, down 49.45% year-over-year, with the annual reading at $137.0 for FY2024, N/A changed from the prior year.
  • Preferred Shares hit $92.0 in Q3 2025 for CorMedix, roughly flat from $92.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $182.0 in Q1 2021 to a low of $92.0 in Q1 2025.
  • Historically, Preferred Shares has averaged $164.5 across 5 years, with a median of $182.0 in 2021.
  • Biggest five-year swings in Preferred Shares: changed 0.0% in 2022 and later tumbled 49.45% in 2025.
  • Year by year, Preferred Shares stood at $182.0 in 2021, then changed by 0.0% to $182.0 in 2022, then changed by 0.0% to $182.0 in 2023, then dropped by 24.73% to $137.0 in 2024, then plummeted by 32.85% to $92.0 in 2025.
  • Business Quant data shows Preferred Shares for CRMD at $92.0 in Q3 2025, $92.0 in Q2 2025, and $92.0 in Q1 2025.